Compare Regeneron Pharmaceuticals Inc (REGN) vs TeraWulf Inc (WULF) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.

WULF trades at $14.40, down 3.81% on the day, amid a volatile period for AI infrastructure stocks. The company shows strong analyst support with 14 buy ratings and a consensus price target of $34.92, but fundamentals reveal challenges: revenue of $168.46M in 2025 was overshadowed by a net loss of -$661.42M, resulting in negative profit margins. Recent news highlights the company's pivot to AI data center hosting, with UBS initiating bullish coverage citing constrained compute supply (UBS, September 23, 2026).

The outlook is bifurcated: analyst optimism contrasts with weak profitability and bearish technical signals. Investment opportunity lies in the AI hosting transition, but risks include persistent losses, high debt-to-asset ratio of 78.84%, and sector volatility. The stock's current price near key support at $14 suggests cautious sentiment despite long-term growth potential in AI infrastructure.